[go: up one dir, main page]

WO2006111251A2 - Extrait hydro-alcoolique de fleurs de butea frondosa, procede pour sa preparation, compositions pharmaceutiques le contenant et son utilisation pour le traitement de l'ulcere - Google Patents

Extrait hydro-alcoolique de fleurs de butea frondosa, procede pour sa preparation, compositions pharmaceutiques le contenant et son utilisation pour le traitement de l'ulcere Download PDF

Info

Publication number
WO2006111251A2
WO2006111251A2 PCT/EP2006/002839 EP2006002839W WO2006111251A2 WO 2006111251 A2 WO2006111251 A2 WO 2006111251A2 EP 2006002839 W EP2006002839 W EP 2006002839W WO 2006111251 A2 WO2006111251 A2 WO 2006111251A2
Authority
WO
WIPO (PCT)
Prior art keywords
hydro
butrin
extract
flowers
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/002839
Other languages
English (en)
Other versions
WO2006111251A3 (fr
Inventor
Andrea Giori
Federico Franceschi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of WO2006111251A2 publication Critical patent/WO2006111251A2/fr
Publication of WO2006111251A3 publication Critical patent/WO2006111251A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

  • the present invention relates to a hydro-alcoholic extract of Butea frondosa flowers for the treatment of ulcer, more particularly to a purified hydro-ethanolic extract of Butea frondosa flowers, the process for its preparation and its use for the treatment of ulcer.
  • Butea frondosa belonging to the class of Fabaceae, is a deciduous tree growing in the Indian subcontinent. It is also known under the name dhak or palas, and is used in Indian traditional medicine for the treatment of various conditions.
  • Previous pharmacological studies evidenced that the aqueous extract of leaves and roots has eye anti-inflammatory activity (S. A. Mengi et al., Indian Journal of Pharmacology, 1995, 27,116-119), the seeds methanolic extract has anti-helminthic activity (D. Prashanth et al., Fitorick, 2001, 72, 421-422), while the triterpene fraction extracted from the flowers exerts anticonvulsive activity (V. S.
  • the present invention relates to the use of purified hydro-ethanolic extract of Butea frondosa flowers for the treatment of ulcer.
  • said purified extract is characterized by:
  • butrin (main component) content 10-70%; • (isobutrin + butein)/(butrin + butin) ratio ranging from 0.3 to 3.
  • the process for the preparation of the purified hydro-ethanolic extract of the invention comprises the following steps: a) grinding of Butea frondosa dry flowers; b) extraction in a percolator with ethanol/water mixtures; c) recovery of the solvent and extraction with ethanol/water fresh mixture, repeating such procedure 5 times; d) filtration of the percolates and subsequent concentration under reduced pressure to obtain a dry residue; e) dissolution of the dry residue in water; f) defatting of the resulting dark solution with hexane; g) removal of the organic phases; h) extraction of the aqueous phase with butanol; i) concentration of the combined organic phases, under reduced pressure; j) drying of the resulting dark syrup under vacuum at 60 0 C for 24 hours; k) grinding of the resulting solid from j).
  • step e) the dark solution from step e) is eluted with water on an adsorption resin column, the resulting fractions are removed, and one or more elutions with ethanol/water mixtures are effected; the combined organic phases are subsequently subjected to the above steps i), j) and k).
  • Example 1 Preparation of the concentrated aqueous extract
  • the material is covered with an ethanol/water 4: 1 v/v mixture and the whole is left at 2O 0 C for 3 hours.
  • the solvent is then percolated and the mass is covered with a fresh portion of ethanol/water 4:1 v/v mixture.
  • the procedure is repeated 5 times totally using approx. 19900 ml of solvent.
  • the 5 percolates are filtered, combined and concentrated under reduced pressure to remove ethanol, thereby obtaining the dry residue (233 g) suspended in water
  • Example 2 The dark solution obtained in Example 1 is concentrated under reduced pressure until obtaining a dark syrup which is dried under vacuum at 60 0 C for 24 hours. The resulting pale brown solid (233 g; yield: 23.3% w/w) is ground to obtain a yellow powder.
  • the product is characterized by a butein, isobutrin, butin and butrin total content of 23.7% w/w (butein: 0.59% w/w; isobutrin 8.02% w/w; butin 1.46% w/w; butrin 13.6% w/w).
  • Example 3 Preparation of the purified extract by liquid-liquid
  • Example 2 The dark solution obtained in Example 1 is defatted with hexane (2 x 1160 ml). The organic phases are separated and discarded. The aqueous phase is then extracted with butanol (7 x 1160 ml). The organic phases are combined and concentrated under reduced pressure until obtaining a dark syrup which is dried under vacuum at 60 0 C for 24 hours. The resulting pale brown solid (100 g; yield: 10% w/w) is ground to obtain a yellow powder.
  • the product is characterized by a butein, isobutrin, butin and butrin total content of 38% w/w (butein: 1.8% w/w; isobutrin 12.6% w/w; butin 4.5% w/w; butrin 19.1% w/w).
  • Example 4 Preparation of the purified extract using an adsorbption resin
  • the dark solution obtained in Example 1 is placed on a column containing 2330 ml of Amberlite XAD 1180 resin, Rohm & Haas, and eluted with water (9320 ml, i.e. 4 bed volumes); the eluted water fractions are discarded. After that, elution is continued with an ethanol/water 7:3 v/v mixture (4660 ml, i.e. 2 bed volumes); the hydro-alcoholic fractions are combined and concentrated under reduced pressure until obtaining a dark syrup which is dried under vacuum at 60 0 C for 24 hours. The resulting pale brown solid (90 g; yield: 9% w/w) is ground to obtain a yellow powder.
  • the product is characterized by a butein, isobutrin, butin and butrin total content of 50.5% w/w (butein: 1.7% w/w; isobutrin 15.7% w/w; butin 6.3% w/w; butrin 26.8% w/w).
  • Example 5 Preparation of the high titre extract by fractionation on an adsorbption resin (fraction A and fraction B)
  • Example 2 The dark solution obtained in Example 1 is placed on a column containing 2330 ml of resin Relite SP 207, Resindion, and eluted with water (23300 ml, i.e. 10 bed volumes ); the eluted water fractions are discarded.
  • the column is then eluted with an ethanol/water 9: 1 v/v mixture (6990 ml, i.e. 3 bed volumes ); the eluate B is concentrated under reduced pressure until obtaining a dark syrup which is dried under vacuum at 6O 0 C for 24 hours.
  • the resulting pale brown solid (32 g; yield: 3.2% w/w) is ground to obtain a yellow powder.
  • the product is characterized by a butein, isobutrin, butin and butrin total content of 51.8% w/w (butein: 3.8% w/w; isobutrin 34.7% w/w; butin 8.6% w/w; butrin 4.7% w/w).
  • the anti-ulcer activity of the extract of Example 1 was tested on two experimental models.
  • the present invention also relates to compositions for the treatment of ulcer, which can be administered through the oral route, containing the extracts described above.
  • Said compositions will be prepared according to conventional methods well-known in pharmaceutical technique, such as those described in "Remington's Pharmaceutical Handbook", Mack Publishing Co., N. Y., USA, together with suitable excipients commonly used in the technique.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne un extrait hydro-alcoolique de fleurs de Butea frondosa pour le traitement de l'ulcère, et notamment un extrait hydro-éthanolique purifié de fleurs de Butea frondosa, son procédé de préparation et son utilisation pour le traitement de l'ulcère.
PCT/EP2006/002839 2005-04-19 2006-03-29 Extrait hydro-alcoolique de fleurs de butea frondosa, procede pour sa preparation, compositions pharmaceutiques le contenant et son utilisation pour le traitement de l'ulcere Ceased WO2006111251A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2005A000691 2005-04-19
IT000691A ITMI20050691A1 (it) 2005-04-19 2005-04-19 Estratto idroalcolico dei fiori di butea frondosa procedimento per la sua preparazione composizioni farmaceutiche che lo contengono e suo uso per il trattamento dell'ulcera

Publications (2)

Publication Number Publication Date
WO2006111251A2 true WO2006111251A2 (fr) 2006-10-26
WO2006111251A3 WO2006111251A3 (fr) 2007-05-10

Family

ID=36940002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/002839 Ceased WO2006111251A2 (fr) 2005-04-19 2006-03-29 Extrait hydro-alcoolique de fleurs de butea frondosa, procede pour sa preparation, compositions pharmaceutiques le contenant et son utilisation pour le traitement de l'ulcere

Country Status (2)

Country Link
IT (1) ITMI20050691A1 (fr)
WO (1) WO2006111251A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099432A3 (fr) * 2006-02-28 2007-11-22 Council Scient Ind Res composition pharmaceutique pour la prévention/le traitement de troubles osseux et son processus d'élaboration
US9775797B2 (en) * 2012-04-03 2017-10-03 Conopco, Inc. Personal care composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7038600A (en) * 1999-08-27 2001-03-26 Cheil Jedang Corporation Extracts derived from pueraria mirifica, butea superba and/or mucuna collettii and extraction thereof
JP2004131390A (ja) * 2002-10-08 2004-04-30 Shiratori Pharmaceutical Co Ltd 抗血栓剤

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099432A3 (fr) * 2006-02-28 2007-11-22 Council Scient Ind Res composition pharmaceutique pour la prévention/le traitement de troubles osseux et son processus d'élaboration
US9775797B2 (en) * 2012-04-03 2017-10-03 Conopco, Inc. Personal care composition

Also Published As

Publication number Publication date
WO2006111251A3 (fr) 2007-05-10
ITMI20050691A1 (it) 2006-10-20

Similar Documents

Publication Publication Date Title
US20010000731A1 (en) Method for the prevention and treatment of chronic venous insufficiency
KR20080038127A (ko) 아티초크 추출물, 이의 용도와 이를 포함하는 제제
JP2002523464A5 (fr)
HU188311B (en) Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents
JP2022545288A (ja) 呼吸器疾患の予防、改善又は効果がある茶組成物及びこれを含む薬学組成物
KR100727121B1 (ko) 타나세툼 파테니움 추출물
WO2011080721A2 (fr) Composition à base de plantes comme agent hépatoprotecteur et traitement pour des troubles hépatiques
JP2010513473A5 (fr)
EP1640016B1 (fr) Préparation et utilisation d'extraits d'asperges sans saponines
US6113909A (en) Pharmaceutical composition containing a mixed extract of Phellodendron amurense RUPRECHT cortex and Patrinia scabiosaefolia FISCH. for treatment of hepatitis C
JP4982337B2 (ja) ヘリコバクター・ピロリに関連する疾患を治療する際の、生姜の根茎から抽出された有効産物の使用
JP3925828B2 (ja) アクテオシドの抽出法
WO2006111251A2 (fr) Extrait hydro-alcoolique de fleurs de butea frondosa, procede pour sa preparation, compositions pharmaceutiques le contenant et son utilisation pour le traitement de l'ulcere
FR2834643A1 (fr) Composition pharmaceutique anti-depressive contenant un extrait de polygala et son procede de preparation
JPS61197523A (ja) 水分散性プロポリス含有製剤の製造法
KR20120068898A (ko) 감염성 질환의 예방, 제거 및 치료를 위한 현삼과 추출물
JP2010516755A (ja) 絡石藤とイチヤクソウの混合抽出物を含有する炎症性疾患の予防及び／又は治療用医薬組成物
KR101647506B1 (ko) 황련 추출물의 독성 저감화 방법, 이로부터 제조된 독성이 저감화된 생약추출물, 및 그 생약추출물을 함유하는 호흡기 질환 예방 또는 치료용 조성물
JP4135933B2 (ja) 鎮咳剤およびその調製方法
KR0163813B1 (ko) 인동으로부터 유효활성 성분을 추출·정제하는 방법과 그 추출물을 함유한 생약조성물
NO791804L (no) Fremgangsmaate for fremstilling av en ekstrakt av stephania cepharanta for terapeutisk anvendelse
KR102293358B1 (ko) 사군자 초임계 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물
CN107648311B (zh) 具有抗病毒和抗炎作用的组合物及药物
KR100552991B1 (ko) 진교로부터 유효 활성 성분의 추출·정제 방법과 그 추출물을함유한 생약 조성물
CN113559142B (zh) 一种杜仲木脂素的提取方法及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06723808

Country of ref document: EP

Kind code of ref document: A2